Showing 3811-3820 of 5956 results for "".
- NASA Astronauts to Headline Heidelberg Engineering’s 2025 International Spectralis Symposiumhttps://modernod.com/news/nasa-astronauts-to-headline-heidelberg-engineerings-2025-international-spectralis-symposium/2482818/Heidelberg Engineering announced that NASA astronauts Warren Hoburg and Tyson Brunstetter, OD, PhD, will lead the keynote presentation at the company’s
- Eylea 8 mg Approved in China for Wet AMDhttps://modernod.com/news/eylea-8-mg-approved-in-china-for-wet-amd/2482817/The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of wet age-related macular degeneration (AMD) in China. The approval is based on positive results from the phase 3 PULSAR trial a
- FDA Approves Genentech’s Susvimo for Diabetic Retinopathyhttps://modernod.com/news/fda-approves-genentechs-susvimo-for-diabetic-retinopathy/2482815/Genentech has received FDA approval for Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR). The approval makes Susvimo the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with one refill ever
- Bausch + Lomb Launches Lumify Preservative Free Redness Reliever Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-preservative-free-redness-reliever-eye-drops-in-the-united-states/2482814/Bausch + Lomb announced the US launch of Lumify Preservative Free redness reliever eye drops, which the company describes as the first and only preservative-free over-the-counter (OTC) eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to m
- Allotex Files IDE with FDA for Collagen-Based Corneal Implanthttps://modernod.com/news/allotex-files-ide-with-fda-for-collagen-based-corneal-implant/2482813/Allotex announced the submission of its investigational device exemption (IDE) to the FDA, marking a step toward US clinical trials of the company’s human collagen-based corneal implant, Allo-1. Allo-1 offers a novel approach to near vision enhancement through biolo
- Grifols Receives FDA Clearance to Initiate Phase 2 Trial of Immunoglobulin Drops for Dry Eye Diseasehttps://modernod.com/news/grifols-receives-fda-clearance-of-ind-application-for-phase-2-trial-of-immunoglobulin-drops-for-dry-eye-disease/2482812/Grifols, a producer of plasma-derived medicines, announced that the FDA has cleared the company’s investigational new drug (IND) application to initiate a phase 2 trial evaluating its immunoglobulin (IG) drops–GRF312 ophthalmic solution–fo
- Atsena Therapeutics Announces Positive Clinical Data for Gene Therapy to Treat X-linked Retinoschisis (XLRS)https://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-for-gene-therapy-to-treat-x-linked-retinoschisis-xlrs/2482808/Atsena Therapeutics announced interim data from Part A of its phase 1/2 LIGHTHOUSE clinical trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study demonstrated a favorable safety profile and compelling signs of efficacy in adul
- New World Medical Introduces Next-Generation Streamline Surgical Systemhttps://modernod.com/news/new-world-medical-introduces-next-generation-streamline-surgical-system-1/2482803/New World Medical has announced the launch of its enhanced Streamline Surgical System, which features a transparent tip designed to provide surgeons with improved visualization of key anatomical structures throughout the procedure. This latest advancement builds upon the original Streamline
- EyeCool Therapeutics Announces Positive Results from Pilot Study in Patients with Chronic Ocular Surface Pain (COSP)https://modernod.com/news/eyecool-therapeutics-announces-positive-results-from-pilot-study-in-patients-with-chronic-ocular-surface-pain-cosp/2482799/EyeCool Therapeutics announced positive clinical data from a double-masked, randomized controlled pilot study of 31 patients in Australia evaluating the safety and efficacy of its investigational device (ETX-4143) for the treatment of Chronic Ocular Surface Pain (COSP). T
- LumiThera’s LIGHTSITE Phase 3B Extension Trial Shows Extended Vision Improvement in Dry AMDhttps://modernod.com/news/lumitheras-phase-3b-extension-trial-topline-results-show-extended-vision-improvement-in-dry-amd-subjects/2482796/LumiThera announced the topline results from the LIGHTSITE 3B extension trial, a prospective, open-label trial in dry age-related macular degeneration (AMD) subjects. The extension trial followed subjects that completed the pivotal LIGHTSITE 3 trial